Is Mesoblast Limited (MESO) Overvalued?
We dive into why Mesoblast Limited (MESO) could be considered overvalued on 2026-08-28, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Commentary & Analysis
Why Mesoblast Limited’s (MESO) Stock Is Down 6.49%
As of Friday, July 17, Mesoblast Limited’s MESO share price has dipped by 6.49%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Mesoblast Limited’s (MESO) Stock Is Up 7.29%
As of Wednesday, July 15, Mesoblast Limited’s MESO share price has surged by 7.29%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Mesoblast Limited’s (MESO) Stock Is Up 5.70%
As of Monday, July 13, Mesoblast Limited’s MESO share price has surged by 5.70%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Mesoblast Limited’s (MESO) Stock Is Up 5.25%
As of Wednesday, July 01, Mesoblast Limited’s MESO share price has surged by 5.25%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | MESO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,967.9 | $257.9 | 54% |
|
| Shares Out (Mil) | 1,297.7 | 54.3 | 95% |
|
| Institutional Ownership | 42.7% | 92.9% | 18% |
|
| Float (Mil) | 859.6 | 41.4 | 90% |
|
| Beta | 0.81 | 0.95 | 48% |
|
| Avg Daily Volume (000s) | 214 | 674 | 43% |
|
| Price Change (52-week) |
(7.0%) | 51.5% | 45% |
|
| Growth | MESO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 74.7% | 13.2% | 98% |
|
| Net Income (5yr) | 10.3% | (10.1%) | 56% |
|
| EPS (5yr) | 23.0% | 15.8% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (47.6%) | (15.6%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | MESO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $120 | $37 | 28% |
|
| Net Income (TTM) (Mil) | ($58) | ($43) | 15% |
|
| EPS (TTM) | ($0.044) | ($1.600) | 37% |
|
| Operating Cash Flow (TTM) (Mil) | ($44) | ($32) | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($59) | $2 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $114 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | $2,201 | $174 | 50% |
|
| Valuation | MESO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 34.35 | 2.51 | 98% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MESO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 80.0% | 68.9% | 89% |
|
| Net Margin | (47.8%) | (72.5%) | 12% |
|
| ROA | (7.4%) | (47.7%) | 27% |
|
| ROE | (9.9%) | (54.9%) | 28% |
|
| Liabilities to Assets | 26.5% | 29.1% | 18% |
|
| F-Score | 5 | 3 | 50% |
|
Mesoblast Limited did not pass any screens on 9/25/2026.
